Vivek Roy

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia
  Blood Cancer Journal 2026 DOI: 10.1038/s41408-026-01497-9
  +Save
• Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis
  Bone Marrow Transplantation 2026 DOI: 10.1038/s41409-025-02760-6
  +Save
• Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide
  Transplantation and Cellular Therapy 2025 DOI: 10.1016/j.jtct.2024.08.009
  +Save
• Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
  Blood Cancer Journal 2024 DOI: 10.1038/s41408-024-01134-3
  +Save
• Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
  Leukemia 2024 DOI: 10.1038/s41375-024-02192-z
  +Save
• Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
  Bone Marrow Transplantation 2023 DOI: 10.1038/s41409-023-02035-y
  +Save
• A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant
  Transplantation and Cellular Therapy 2023 DOI: 10.1016/j.jtct.2023.02.001
  +Save
• RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
  Blood Cancer Journal 2022 DOI: 10.1038/s41408-022-00662-0
  +Save
• Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia
  Clinical Lymphoma Myeloma and Leukemia 2021 DOI: 10.1016/j.clml.2021.01.002
  +Save
• Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
  Case Reports in Hematology 2020 DOI: 10.1155/2020/4360926
  +Save